FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328118675> ?p ?o ?g. }

• W4328118675 abstract "Introduction The use of Y-90 radioembolization techniques has become a standard tool for the treatment of liver cancer and metastatic diseases that result in liver lesions. As there are only two approved forms of radioembolization therapy, the procedures for use are also fairly standardized even though exact international and interdepartmental procedures can vary. What has been less published over the years are the nuanced differences in delivery techniques and handling of the two available Y90 radioembolization therapies. This paper seeks to examine various aspects of delivery techniques, product handling, and radiation exposure that differ between the available and approved products. Understanding these differences can assist with providing more efficient treatment, confirmation of accurate therapy, more informed handling of the products, and improved training of physicians and other hospital staff. Methods Two commercially available and approved radioembolization devices were compared to assess nuanced, but key differences between the available products regarding therapy delivery, handling of the products, and radiation exposure to patients and staff. This work is broken into two sections: (1) Therapy Delivery, (2) Radiation Safety. Therapy delivery characteristics were assessed by using an external radiation detector system with detectors placed inside of each delivery system facing the dose vial and on the output catheter lines to the patient. Additional detectors were placed near the liver of the patient and on top of the foot to measure extremities. Data were acquired continuously throughout therapy delivery to collect time activity curves (TACs) for the characterization of each therapy. These data were analyzed to assess if (a) real-time monitoring of radiation could be used to provide an accurate assessment of residual dose before the patient leaves the procedure room, and (b) can dose delivery characteristics be observed that enable improved training and quality control. Calculation of residual dose using the external detector TACs was performed by analyzing initial and final activity peaks to determine measured count rate differences. Radiation safety aspects were assessed by monitoring radiation exposure to staff handling each of the available therapy products. Nuclear medicine technologists and interventional radiology physician body and hand doses were measured for each delivered therapy using standard body and ring dosimeters. The TACs noted above collected for the liver and extremities were used to assess if any off-target or leached Y90 activity could be detected for each therapy. Blood was collected at times before, during, and after treatment and then counted on a gamma counter to assess differences in free Y90 circulating in the blood. Each patient in this study also received a post-treatment whole-body PET/CT at 2–4 h post-infusion to assess for any aggregate free Y90 deposition that may have resulted from circulating free Y90 in the subject following therapy. Results Calculations of residual dose in the vial following therapy using the real-time detection methods resulted in values that were not statistically different from the values calculated by nuclear medicine following the procedure ( <mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=IM1><mml:mi>p</mml:mi><mml:mo>></mml:mo><mml:mn>0.05</mml:mn></mml:math> ). Real-time collection of dose delivery data enabled observation of key characteristics related to each delivery method. For SIR-spheres procedures, the cycle of pushing the dose and visualizing with fluoro can easily be seen with each push resulting in a smaller and smaller peak with intermittent fluoroscopy pulses. TheraSpheres infusions show a rapid bolus with nearly all of the measurable injected activity being infused in the first push of the dose. Staff radiation exposure assessments showed statistically significant differences between glass and resin spheres for hand doses of physicians and technologists ( p &gt; 0.05), but no statistical difference between body doses for both products ( <mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=IM2><mml:mi>p</mml:mi><mml:mo>></mml:mo><mml:mn>0.05</mml:mn></mml:math> ). Assessments of free Y90 circulating during therapy showed that patients undergoing therapies with resin spheres had post-infusion blood levels that were 120% higher than pre-infusion levels while glass sphere therapy patients only saw a 7% rise in post-infusion blood levels. The coefficients of variation (COVs) across glass sphere measurements pre, during, and post, were only 0.008 while resin sphere measures saw much greater variability with a COV of 0.45. Both glass and resin therapies showed blood levels at 2–4 h post-injection to be similar to levels measured pre-injection. Neither therapy showed any signs of focal aggregation at 2–4 h post-infusion on whole-body PET/CT. Conclusion Although glass and resin radioembolization therapies are similar, they both have unique characteristics related to their administration and handling by staff. Understanding the nuances can assist in providing more efficient delivery, better staff education, and reducing radiation exposure to everyone involved with these therapies. The use of near real-time monitoring is feasible and can be used to obtain critical information about the delivery success of a therapy and can inform physicians on their techniques to optimize their practice as well as provide more consistent training to residents." @default.
• W4328118675 created "2023-03-22" @default.
• W4328118675 creator A5013784950 @default.
• W4328118675 creator A5022334133 @default.
• W4328118675 creator A5023459505 @default.
• W4328118675 creator A5033357552 @default.
• W4328118675 creator A5054674435 @default.
• W4328118675 creator A5062100055 @default.
• W4328118675 creator A5062554135 @default.
• W4328118675 creator A5088406883 @default.
• W4328118675 creator A5089804025 @default.
• W4328118675 date "2023-03-21" @default.
• W4328118675 modified "2023-09-26" @default.
• W4328118675 title "Insights into handling and delivery of Y-90 radioembolization therapies" @default.
• W4328118675 cites W2034342132 @default.
• W4328118675 cites W2103426950 @default.
• W4328118675 cites W2132585658 @default.
• W4328118675 cites W2297372456 @default.
• W4328118675 cites W2593049405 @default.
• W4328118675 cites W2603497413 @default.
• W4328118675 cites W2896429003 @default.
• W4328118675 cites W2941388073 @default.
• W4328118675 cites W2949348039 @default.
• W4328118675 cites W2990244017 @default.
• W4328118675 cites W3003832503 @default.
• W4328118675 cites W3119741834 @default.
• W4328118675 cites W3128646645 @default.
• W4328118675 cites W3147142721 @default.
• W4328118675 cites W3152073565 @default.
• W4328118675 cites W3199442989 @default.
• W4328118675 cites W4205569085 @default.
• W4328118675 cites W4283654372 @default.
• W4328118675 cites W4285492642 @default.
• W4328118675 doi "https://doi.org/10.3389/fnume.2023.1075782" @default.
• W4328118675 hasPublicationYear "2023" @default.
• W4328118675 type Work @default.
• W4328118675 citedByCount "0" @default.
• W4328118675 crossrefType "journal-article" @default.
• W4328118675 hasAuthorship W4328118675A5013784950 @default.
• W4328118675 hasAuthorship W4328118675A5022334133 @default.
• W4328118675 hasAuthorship W4328118675A5023459505 @default.
• W4328118675 hasAuthorship W4328118675A5033357552 @default.
• W4328118675 hasAuthorship W4328118675A5054674435 @default.
• W4328118675 hasAuthorship W4328118675A5062100055 @default.
• W4328118675 hasAuthorship W4328118675A5062554135 @default.
• W4328118675 hasAuthorship W4328118675A5088406883 @default.
• W4328118675 hasAuthorship W4328118675A5089804025 @default.
• W4328118675 hasBestOaLocation W43281186751 @default.
• W4328118675 hasConcept C126838900 @default.
• W4328118675 hasConcept C127413603 @default.
• W4328118675 hasConcept C189942447 @default.
• W4328118675 hasConcept C19527891 @default.
• W4328118675 hasConcept C2781267111 @default.
• W4328118675 hasConcept C42360764 @default.
• W4328118675 hasConcept C509974204 @default.
• W4328118675 hasConcept C71924100 @default.
• W4328118675 hasConceptScore W4328118675C126838900 @default.
• W4328118675 hasConceptScore W4328118675C127413603 @default.
• W4328118675 hasConceptScore W4328118675C189942447 @default.
• W4328118675 hasConceptScore W4328118675C19527891 @default.
• W4328118675 hasConceptScore W4328118675C2781267111 @default.
• W4328118675 hasConceptScore W4328118675C42360764 @default.
• W4328118675 hasConceptScore W4328118675C509974204 @default.
• W4328118675 hasConceptScore W4328118675C71924100 @default.
• W4328118675 hasFunder F4320310567 @default.
• W4328118675 hasLocation W43281186751 @default.
• W4328118675 hasOpenAccess W4328118675 @default.
• W4328118675 hasPrimaryLocation W43281186751 @default.
• W4328118675 hasRelatedWork W161339683 @default.
• W4328118675 hasRelatedWork W1995844504 @default.
• W4328118675 hasRelatedWork W2024362341 @default.
• W4328118675 hasRelatedWork W2041825105 @default.
• W4328118675 hasRelatedWork W2068265501 @default.
• W4328118675 hasRelatedWork W2076862816 @default.
• W4328118675 hasRelatedWork W2351982879 @default.
• W4328118675 hasRelatedWork W2384708512 @default.
• W4328118675 hasRelatedWork W2410998211 @default.
• W4328118675 hasRelatedWork W4322705987 @default.
• W4328118675 hasVolume "3" @default.
• W4328118675 isParatext "false" @default.
• W4328118675 isRetracted "false" @default.
• W4328118675 workType "article" @default.